A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
Latest Information Update: 31 Jul 2025
At a glance
- Drugs NPT 2042 (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Neuropro Therapeutics
Most Recent Events
- 16 Jul 2025 Status changed from recruiting to completed.
- 24 Dec 2024 Planned End Date changed from 30 Dec 2024 to 30 Jul 2025.
- 24 Dec 2024 Planned primary completion date changed from 30 Nov 2024 to 1 Jun 2025.